
RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), Resonance Health Ltd (ASX: RHT) (**Resonance Health** or **Company**) provides the results of the 2021 Annual General Meeting (**AGM**) held earlier today, which are set out in the attached schedule together with the details of the proxy votes and votes cast in respect of each resolution.

All resolutions put to the AGM were decided by a poll.

Enquiries:

Nick Allan – Company Secretary

E: nicka@resonancehealth.com

P: +61 (0)8 9286 5300

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of non-invasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. A number of these SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan®** - provides an accurate measurement of liver iron concentration (**LIC**) through a non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. FerriScan is internationally recognised as the gold standard in LIC assessment
- **FerriSmart®** - an AI-driven system for the automated real-time measurement of LIC in patients using non-invasive MRI-based technology
- **HepaFat-Scan®** - an MRI-based solution which provides a reliable non-invasive measure of liver fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty liver disease
- **HepaFat-AI®** - an AI-driven system for the automated real-time multi-metric measurement of liver fat in patients using non-invasive MRI-based technology

The Company has an active development pipeline of additional medical imaging analysis products and services, including **LiverSmart™**, which combines FerriSmart® and HepaFat-AI® into a single multi-parametric MRI session and **Alert-PE™**, an AI tool for the automated review of chest CT scans of patients with suspected pulmonary embolism.

RESONANCE HEALTH LTD
ANNUAL GENERAL MEETING
Thursday, 25 November 2021
Results of Meeting

Resolution	Resolution Details	Resolution Type	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
			For	Against	Proxy's Discretion	Abstain*	For	Against	Abstain*	
1	Adoption Of Remuneration Report	Ordinary	64,608,916 99.5%	237,682 0.4%	112,169 0.2%	0	70,154,948 99.7%	237,682 0.3%	0	Carried
2	Re-Election of Mr Simon Panton as a Director	Ordinary	145,931,396 99.8%	41,911 0.0%	246,487 0.2%	0	151,611,746 100.0%	41,911 0.0%	0	Carried
5	Approval Of Additional 10% Placement Facility	Special	145,378,111 99.5%	530,066 0.4%	196,487 0.1%	115,130	151,008,461 99.7%	530,066 0.3%	115,130	Carried
4	Adoption of the Resonance Long Term Incentive Plan	Ordinary	59,588,029 91.9%	5,073,558 7.8%	183,485 0.3%	113,695	65,205,377 92.8%	5,073,558 7.2%	113,695	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.